Sun Liwei, Sha Jichao, Meng Cuida, Zhu Dongdong
Department of Otolaryngology Head and Neck Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Stem Cells Int. 2020 Jun 10;2020:2367524. doi: 10.1155/2020/2367524. eCollection 2020.
Allergic rhinitis (AR) is a prevalent disorder that causes a significant and often underestimated health burden for individuals and society. The current drug treatment cannot essentially deal with the regulation of the allergic reaction, while the allergic symptoms could be alleviated. Mesenchymal stem cells (MSCs) bear a variety of properties, such as the ability to differentiate into various cell lineages, to secrete soluble factors crucial for cell survival and proliferation, to migrate to the exact site of injury, and to modulate the immune response. Clinical studies have been extensively conducted in MSCs as the models for varieties of diseases such as neurological diseases. Due to their immunomodulatory properties, the MSCs have gradually been believed to become one of the promising strategies for AR treatments although so far the MSCs-mediated treatment for AR is still at animal experiments stage. Fully understanding the roles and mechanisms of MSCs immunomodulatory effects serves as the prerequisite that will be beneficial to the application of MSCs-based AR clinical treatment methods. In this review article, we highlighted the recent research advances and give a brief perspective in the future study of the MSCs-mediated therapeutic application in AR treatments.
变应性鼻炎（AR）是一种常见疾病，给个人和社会带来了重大且常常被低估的健康负担。目前的药物治疗虽能缓解变应性症状，但无法从根本上应对过敏反应的调控。间充质干细胞（MSCs）具有多种特性，如能够分化为各种细胞谱系、分泌对细胞存活和增殖至关重要的可溶性因子、迁移至损伤的确切部位以及调节免疫反应。作为神经疾病等多种疾病的模型，MSCs已开展了广泛的临床研究。由于其免疫调节特性，尽管目前MSCs介导的AR治疗仍处于动物实验阶段，但MSCs逐渐被认为是AR治疗的有前景的策略之一。充分了解MSCs免疫调节作用的角色和机制是有利于基于MSCs的AR临床治疗方法应用的前提条件。在这篇综述文章中，我们重点介绍了近期的研究进展，并对MSCs介导的治疗在AR治疗中的未来研究给出了简要展望。
